Alimentary Pharmacology & Therapeutics

Article	Citations
	145
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis	143
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC	138
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease	113
AP&T: Editors' Declarations of Interest	106
	83
Issue Information	72
Issue Information	72
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep	71
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?	69
	68
Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy	67
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation	67
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease	65
Editorial: The future of managing drug induced liver injury	64
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC	63
No value of non‐selective beta‐blockers after TIPS‐insertion	62
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted	62
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply	59
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?	58
Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study	58
Systematic review and meta‐analysis: the incidence and prevalence of paediatric coeliac disease across Europe	57
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply	57
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply	55
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis	55

Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study	55
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B	53
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US	52
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply	52
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o	50
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough	50
Editorial: is there a ‘precursor’ HCC lesion and can it be detected by hepatobiliary contrast‐enhanced magnetic resonance imaging? Authors' reply	49
Editorial: liver disease in secondary care—‘money or your life’. Authors' reply	48
Editorial: Plants against animals	48
Letter: is wireless oesophageal pH monitoring the best technique to evaluate night‐time reflux?	47
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?	47
Liver biopsy in the real world—reporting, expert concordance and correlation with a pragmatic clinical diagnosis	47
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease	46
Editorial: risk of pneumonia in IBD—reading between the lines!	46
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients	45
Letter: Ozanimod and latent tuberculosis	44
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease	44
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply	43
Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply	42
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?	42
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply	42
Gut‐brain axis dysfunction underlies FODMAP‐induced symptom generation in irritable bowel syndrome	41
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension	41
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment	41
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply	41
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?	41
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score	40
Editorial: Can we predict or not predict response to hypnotherapy? That is the question	39
Development of a model to identify patients who do not need oesophageal biopsies when eosinophilic oesophagitis is suspected	39
Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease	38
Schizophrenia and risk of new‐onset inflammatory bowel disease: a nationwide longitudinal study	38
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis	38
Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases	38
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials	38
Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment	38
Prevalence, symptoms and risk factor profile of rumination syndrome and functional dyspepsia: a population‐based study	37
Diagnostic Accuracy of an Add‐On, Blood‐Based Screening Test for Colorectal Cancer in Two Established Screening Programmes	37
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply	37
Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor	36
Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection	36
Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification	36
Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome	35
Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV‐Infected HCC Patients Undergoing Immunotherapy	34
	34
Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease	34
Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras	34
Issue Information	34
	34
Issue Information	33
Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Cons	33

Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome	33
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure	33
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply	32
	32
	32
Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply	32
Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC	32
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas	32
	32
Editorial: Feeling better about NASH—Authors' reply	31
Letter: normalizing the ileoanal pouch—more than a one‐step technique. Authors' reply	31
Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply	31
Letter: Baveno‐VI criteria to exclude large varices in patients with hepatocellular carcinoma—What have we learned?	31
Trends in aetiology‐based hospitalisation for cirrhosis before and during the COVID‐19 pandemic in the United States	31
The impact of red blood cell transfusion practices on inpatient mortality in variceal and non‐variceal gastrointestinal bleeding patients: a 20‐year US nationwide retrospective analysis	31
Letter: fighting the battle but losing the war—inflammatory bowel disease and venous thromboembolism	30
Letter: response of eosinophilic oesophagitis to proton pump inhibitor therapy—the importance of biopsies at index endoscopy	30
Letter: safety of immune checkpoint inhibitors in patients with pre‐established microscopic colitis—a single‐centre experience	30
Editorial: finding the ideal prokinetic for gastroparesis—we are not there yet	30
Editorial: inconclusive diagnosis of GERD—are new parameters in impedance‐pH‐metry ready for clinical use?	30
Editorial: reducing false alarms with oesophagogastric junction outflow obstruction	30
Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring	30
Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'	30
Editorial: food insecurity, diet quality, racial and ethnic disparities in non‐alcoholic fatty liver disease	29
Editorial: changes of health‐related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD—authorsʼ reply	29
Editorial: Crystalising the burden of steatotic liver disease—Authors' reply	29
Autoimmune hepatitis and metabolic syndrome‐associated disease development: a U.S. cohort study	29
Letter: COVID‐19 outcomes and anti‐TNF treatments—comprehensive evidence matters	28
Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment	28
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality	28
Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis—still a long way to go! Authors' reply	28
Letter: chronic HDV infection—is ignorance bliss? Authors' reply	28
Letter: The importance of histological assessment—a further stride inSTRIDE. Authors' reply	28
Letter: Are we forgetting the importance of steatosis in steatotic liver disease? Authors' reply	28
Editorial: time to eat? Skipping breakfast in metabolic‐associated fatty liver disease	28
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis	28
Letter: the value of quality liver biopsy before initiation of corticosteroids for severe alcoholic hepatitis	28
Letter: hereditary role in non‐alcoholic fatty liver disease	27
Review article: current and emerging therapies for acute alcohol‐associated hepatitis	27
Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments	27
Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound	27
Letter: Irritable bowel syndrome and antibiotics—Authors' reply	27
Letter: association between COVID‐19 and inflammatory bowel disease	27
Faecal incontinence: Retentive, non‐retentive and when to suspect organic pathology	27
Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers	27
Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients	27
Letter: diet‐responsive or just diet‐adherent in eosinophilic oesophagitis. Where is the dietitian?	26
Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply	26
Letter: the diagnostic value of ultrasound‐based versus CT‐based sarcopenia measurement in cirrhosis	26
Letter: the hidden reasons of long‐term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication	25
Letter: Albumin—Does formulation matter?	25
Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study	25
Editorial: Negative impact of diabetes mellitus and obesity on the prognosis of patients with chronic liver disease—Authors' reply	25
Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply	25
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study	25
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection	25
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients	25
Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma—ready for their use?	24
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs	24
Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologi	24
Systematic review: The use of large language models as medical chatbots in digestive diseases	24
Editorial: an elastography‐based two‐step approach to detect NAFLD with compensated advanced chronic liver disease—authors' reply	24
Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy	24
Progressive alcohol‐related liver fibrosis is characterised by imbalanced collagen formation and degradation	24
Trends in the prevalence rates and predictive factors of coeliac disease: A long‐term nationwide follow‐up study	23
Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?	23
Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply	23
CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance	23
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States	23
	23
Issue Information	23
Issue Information	23
	23
	23
Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States	22
Editorial: The use of Baveno VI and VII criteria in patients with hepatocellular carcinoma	22
Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis	22
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply	22
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality	22
Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply	22

Early serum ammonia variation in critically ill patients with cirrhosis: A multicentre cohort study	22
Editorial: group‐based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome—authors' reply	22
Letter: efficacy of peppermint oil in irritable bowel syndrome	22
Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis?	22
Real‐Time Assessment of H. pylori Infection to Guide Molecular Antibiotic Resistance Testing: A Combined Endoscopy‐Gastric Juice Analysis Approach	22
	22
Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C	22
Letter: Should ulcerative colitis be monitored more or less invasively?	22
Editorial: PPIs and gastric cancer – Are we dealing with a carcinogen? Authors' reply	22
Editorial: lack of gastrointestinal symptoms caused by gluten in patients without coeliac disease—time to ditch the ‘gluten’ from ‘non‐coeliac gluten sensitivity’	22
Letter: assessment of histological disease activity in Crohn's disease clinical trials—a step in the right direction, but further optimisation needed	22
Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?	22
	22
Editorial: safety of thiopurines in pregnancy—considering the mother, foetus and newborn	22
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study	22
Editorial: One step closer to personalised nutrition therapy for irritable bowel syndrome	22
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection—Authors' reply	22
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome	21
Natural history and impact of irritable bowel syndrome‐type symptoms in inflammatory bowel disease during 6 years of longitudinal follow‐up	21
No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies	21
Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply	21
Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission	21
Editorial: potassium‐competitive acid blockers—is there a role for more complete acid suppression?	21
Letter: efficacy of peppermint oil in irritable bowel syndrome—authors' reply	21
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease	21
Systematic review with meta‐analysis: the long‐term efficacy of Barrett's endoscopic therapy—stringent selection criteria and a proposal for definitions	21
Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. population‐based study	21
Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease	21
Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV<	21
Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018	20
Letter: mind the gap—search and publication date of systematic reviews and meta‐analysis. Authors' reply	20
Editorial: improving the use of Montreal classification through a bidirectional approach	20
Letter: Shifting focus—From ChatGPT to specialised medical LLMs	20
Editorial: higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn's disease	20
Type 1 diabetes and microscopic colitis: A nationwide matched case–control study in Sweden	20
Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post‐inflammatory polyps	20
Letter: universal screening for hepatitis C in pregnant women, children and adolescents	20
Limited evidence of moderation of the association between gastrointestinal symptoms and prospective healthcare utilisation by quality of life	19
Effect of time to pre‐emptive transjugular intrahepatic portosystemic shunt on patient outcome, a UK multicentre cohort study	19
Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis	19
Systematic review with meta‐analysis: The effects of non‐steroidal anti‐inflammatory drugs and anti‐platelet therapy on the incidence and recurrence of hepatocellular carcinoma	19
Issue Information	19
Issue Information	19
Letter: neuromodulators in functional dyspepsia—the right indication in the right dose. Authors’ reply	19
Review article: Faecal biomarkers for assessing small intestinal damage in coeliac disease and environmental enteropathy	19
Age at treatment initiation predicts response in children with chronic hepatitis B	19
Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone	19
Issue Information	19
Novel microbiome signatures for non‐invasive diagnosis of adenoma recurrence after colonoscopic polypectomy	19
Systematic review with meta‐analysis: effects of implementing a nutrition support team for in‐hospital parenteral nutrition	19
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver	19
Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent	19
Home‐based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites	19
Systematic review with meta‐analysis: artificial intelligence in the diagnosis of oesophageal diseases	19
	19
Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply	18
Letter: PCSK9 inhibitor for liver transplant patients during the post‐statin era?	18
Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’	18
Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply	18
Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply	18
Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people	18
Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game. Authors' reply	18
Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply	18
Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B	18
Letter: predictive role of magnetic resonance elastography in chronic liver disease – still a long way to go	18
Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF	18
Editorial: colorectal cancer in elderly‐onset inflammatory bowel disease—what is the risk?	18
Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!	18
Presence of high‐risk HLA genotype is the most important individual risk factor for coeliac disease among at‐risk relatives	18
Editorial: The use of Baveno VI and VII criteria for portal hypertension and varices in patients with hepatocellular carcinoma—Authors' reply	18
Editorial: Faecal microbiota transplantation inIBS—Moving closer or away from success? Authors' reply	17
Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management	17
Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease—a Danish cohort study	17
Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study	17
Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum	17
Long‐term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study	17
Systematic review: hepatitis C viraemic allografts to hepatitis C‐negative recipients in solid organ transplantation	17
Editorial: non‐erosive reflux disease is often not GERD—time to change the definition or abandon the term?	17
Superficial oesophageal mucosal innervation may contribute to severity of symptoms in oesophageal motility disorders	17
Editorial: Bile acid diarrhoea – simplified clinico‐biochemical diagnosis	17
Altered serum bile acid composition is associated with cardiac dysfunction in cirrhosis	17
Editorial: immunosuppression and SARS‐CoV‐2 vaccination—where do we stand?	17
Letter: fighting the battle but losing the war—inflammatory bowel disease and venous thromboembolism. Authors' reply	17
Systematic review with meta‐analysis: incidence and factors for progression to advanced neoplasia in inflammatory bowel disease patients with indefinite and low‐grade dysplasia	17
Editorial: COVID‐19 vaccines are safe and effective in patients with inflammatory bowel disease—but many unanswered questions remain	17
Editorial: the other bug	17
Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study	16
Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation	16
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors’ reply	16
Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply	16
Retrospective review of patients treated for cyclic vomiting syndrome with topiramate	16
Review article: Emerging and current management of acute‐on‐chronic liver failure	16
Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study	16
Epidemiology and risk factors for histopathologic characteristics of non‐alcoholic fatty liver disease in South America	16
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet?	16